Suppr超能文献

用于乳铁蛋白眼部控释给药的黏膜黏附性聚乳酸-羟基乙酸共聚物纳米球和纳米囊

Mucoadhesive PLGA Nanospheres and Nanocapsules for Lactoferrin Controlled Ocular Delivery.

作者信息

Varela-Fernández Rubén, García-Otero Xurxo, Díaz-Tomé Victoria, Regueiro Uxía, López-López Maite, González-Barcia Miguel, Isabel Lema María, Otero-Espinar Francisco Javier

机构信息

Department of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela (USC), Campus Vida, 15782 Santiago de Compostela, Spain.

Clinical Neurosciences Group, University Clinical Hospital, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.

出版信息

Pharmaceutics. 2022 Apr 6;14(4):799. doi: 10.3390/pharmaceutics14040799.

Abstract

BACKGROUND

the present work describes the preparation, characterization and optimization of eight types of PLGA-based nanosystems (nanospheres and nanocapsules) as innovative mucoadhesive drug delivery systems of lactoferrin, in order to achieve a preclinical consistent base as an alternative pharmacological treatment to different ocular syndromes and diseases.

METHODS

All different nanoparticles were prepared via two modified nanoprecipitation techniques, using a three-component mixture of drug/polymer/surfactant (Lf/PLGA/Poloxamer), as a way to overcome the inherent limitations of conventional PLGA NPs. These modified polymeric nanocarriers, intended for topical ophthalmic administration, were subjected to in vitro characterization, surface modification and in vitro and in vivo assessments.

RESULTS

An appropriate size range, uniform size distribution and negative ζ potential values were obtained for all types of formulations. Lactoferrin could be effectively included into all types of nanoparticles with appropriate encapsulation efficiency and loading capacity values. A greater, extended, and controlled delivery of Lf from the polymeric matrix was observed through the in vitro release studies. No instability or cytotoxicity was proved for all the formulations by means of organotypic models. Additionally, mucoadhesive in vitro and in vivo experiments show a significant increase in the residence time of the nanoparticles in the eye surface.

CONCLUSIONS

all types of prepared PLGA nanoparticles might be a potential alternative for the topical ophthalmic administration of lactoferrin.

摘要

背景

本研究描述了八种基于聚乳酸-羟基乙酸共聚物(PLGA)的纳米系统(纳米球和纳米囊)的制备、表征及优化,将其作为乳铁蛋白的新型黏膜黏附药物递送系统,旨在为不同眼部综合征和疾病的替代药物治疗建立临床前一致基础。

方法

所有不同的纳米颗粒均通过两种改良的纳米沉淀技术制备,使用药物/聚合物/表面活性剂(Lf/PLGA/泊洛沙姆)的三组分混合物,以克服传统PLGA纳米颗粒的固有局限性。这些旨在用于局部眼科给药的改良聚合物纳米载体,进行了体外表征、表面修饰以及体外和体内评估。

结果

所有类型的制剂均获得了合适的粒径范围、均匀的粒径分布和负ζ电位值。乳铁蛋白能够以适当的包封率和载药量有效地包载到所有类型的纳米颗粒中。通过体外释放研究观察到Lf从聚合物基质中实现了更大、更持久且可控的释放。通过器官型模型证明所有制剂均无不稳定性或细胞毒性。此外,体外和体内黏膜黏附实验表明纳米颗粒在眼表的停留时间显著增加。

结论

所有制备的PLGA纳米颗粒可能是乳铁蛋白局部眼科给药的潜在替代物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4129/9029159/77e613de3032/pharmaceutics-14-00799-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验